U.S. Markets close in 1 hr 41 mins

Weakness Seen in Aegerion Pharmaceuticals (AEGR) Estimates: Should You Stay Away?

Zacks Equity Research

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Aegerion Pharmaceuticals, Inc. (AEGR), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in AEGR.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 6 estimates moving down in the past 30 days, compared with no upward revision. This trend has caused the consensus loss estimate to widen, going from a loss of 30 cents a share a month ago to its current loss of 88 cents.

Also, for the current quarter, Aegerion Pharmaceuticals has seen 5 downward estimate revisions versus no revision in the opposite direction, widening the consensus loss estimate from a loss of 15 cents per share to a loss of 39 cents over the past 30 days.   

The stock also has seen some pretty dismal trading lately, as the share price has dropped 26.6% in the past month.

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the pharmaceutical sector, you may instead consider some better-ranked stocks including ANI Pharmaceuticals, Inc. (ANIP), Gilead Sciences Inc. (GILD) and Illumina Inc. (ILMN). All these stocks hold a Zacks Rank #1 (Strong Buy) and may be better selections at this time.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Zacks Investment Research